AUROBINDO

June 7, 2019

To	To
Listing Department, **NATIONAL STOCK EXCHANGE OF INDIA LIMITED** Exchange Plaza, Bandra Kurla Complex, Bandra (E), **MUMBAI -400 051** **Company Code No. AUROPHARMA**	The Corporate Relations Department **BSE LIMITED** Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, **MUMBAI -400 001** **Company Code No. 524804**

Dear Sirs,

Sub: Clarification on media report "Bankrupt US drug firm Aceto accuses Aurobindo of sabotage, seeks damages".
Ref : Emails dated June 6, 2019 from BSE Ltd & NSE.

This has reference to your above cited emails seeking clarification on the subject matter.

This is to inform that the Company, Aurolife Pharma LLC, a step-down wholly owned subsidiary in USA and Mr. P.V. Ramprasad Reddy, our Director have been made party to a litigation proceeding in the United States of America and a copy of proceeding is yet to be received.

We deny all the contentions and allegations set out and alluded to in the media report.

On preliminary examination of the compliant, the Company has been advised by its legal advisors that the case appears to be devoid of merits and consists of baseless allegations against the Company, Aurolife and Mr. P.V. Ramprasad Reddy alleging fraud, negligent misrepresentation and the failure of the Company and Aurolife to fulfill their obligations, *inter-alia*, under a supply contract entered into with the Company.

Please take the information on record.

Thanking you,

Yours faithfully,
For AUROBINDO PHARMA LIMITED

AUROBINDO PHARMA LTD. HYD.

B.Adi Reddy
Company Secretary